J&J TREMFYA long-term data show sustained remission in ulcerative colitis through 3 years

 

More than 80% of those treated with TREMFYA^® were in clinical remission and more than 50% were in endoscopic remission at Week 140 of the QUASAR long-term extension study, showing lasting disease control for patients

78% of patients achieved intestinal healing at both the tissue and visual level (histo-endoscopic mucosal improvement)

https://www.jnj.com/media-center/press-releases/tremfya-guselkumab-long-term-data-show-sustained-clinical-and-endoscopic-remission-in-ulcerative-colitis-through-3-years